+关注
幸运无敌_8833
暂无个人介绍
IP属地：0
5
关注
0
粉丝
1
主题
0
勋章
主贴
热门
幸运无敌_8833
2024-12-14
这篇文章不错，转发给大家看看
@曹干:我开仓了
$纳指三倍做多ETF(TQQQ)$
,呵呵，新高来了
幸运无敌_8833
2023-10-03
$京东(JD)$
11。11。11。
美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3569549791948201","uuid":"3569549791948201","gmtCreate":1606455768571,"gmtModify":1606458895956,"name":"幸运无敌_8833","pinyin":"xywd8833xingyunwudi8833","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/9dacd5d2a7077a41b394190b7ed47d47","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.05","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.88%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.84%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"0","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":381405223952720,"gmtCreate":1734160605234,"gmtModify":1734161137103,"author":{"id":"3569549791948201","authorId":"3569549791948201","name":"幸运无敌_8833","avatar":"https://static.tigerbbs.com/9dacd5d2a7077a41b394190b7ed47d47","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569549791948201","authorIdStr":"3569549791948201"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/381405223952720","repostId":"377461792997392","repostType":1,"repost":{"id":377461792997392,"gmtCreate":1733182380221,"gmtModify":1746576330674,"author":{"id":"3459405299593947","authorId":"3459405299593947","name":"曹干","avatar":"https://static.tigerbbs.com/8710ff7a49df5b7bcdb6338bac4d0eb8","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3459405299593947","authorIdStr":"3459405299593947"},"themes":[],"htmlText":"我开仓了<a href=\"https://laohu8.com/S/TQQQ\">$纳指三倍做多ETF(TQQQ)$ </a>,呵呵，新高来了","listText":"我开仓了<a href=\"https://laohu8.com/S/TQQQ\">$纳指三倍做多ETF(TQQQ)$ </a>,呵呵，新高来了","text":"我开仓了$纳指三倍做多ETF(TQQQ)$ ,呵呵，新高来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377461792997392","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":226607236358392,"gmtCreate":1696332101119,"gmtModify":1696334095456,"author":{"id":"3569549791948201","authorId":"3569549791948201","name":"幸运无敌_8833","avatar":"https://static.tigerbbs.com/9dacd5d2a7077a41b394190b7ed47d47","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569549791948201","authorIdStr":"3569549791948201"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$ </a>11。11。11。","listText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$ </a>11。11。11。","text":"$京东(JD)$ 11。11。11。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/226607236358392","repostId":"1150270900","repostType":2,"repost":{"id":"1150270900","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1696330222,"share":"https://www.laohu8.com/m/news/1150270900?lang=&edition=full","pubTime":"2023-10-03 18:50","market":"us","language":"zh","title":"美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150270900","media":"老虎资讯综合","summary":"10月3日，Point Biopharma盘前直线涨超82%，礼来以12.50美元/股的价格将其收购","content":"<html><head></head><body><p>10月3日，Point Biopharma盘前直线涨超82%，<a href=\"https://laohu8.com/S/LLY\">礼来</a>将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2babea8249e8c38accee176b179d490\" title=\"\" tg-width=\"817\" tg-height=\"480\"/></p><p>资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2023-10-03 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>10月3日，Point Biopharma盘前直线涨超82%，<a href=\"https://laohu8.com/S/LLY\">礼来</a>将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2babea8249e8c38accee176b179d490\" title=\"\" tg-width=\"817\" tg-height=\"480\"/></p><p>资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","PNT":"POINT BIOPHARMA GLOBAL INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4581":"高盛持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LLY":"礼来"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150270900","content_text":"10月3日，Point Biopharma盘前直线涨超82%，礼来将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。","news_type":1,"symbols_score_info":{"LLY":1,"PNT":1.1}},"isVote":1,"tweetType":1,"viewCount":1006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":381405223952720,"gmtCreate":1734160605234,"gmtModify":1734161137103,"author":{"id":"3569549791948201","authorId":"3569549791948201","name":"幸运无敌_8833","avatar":"https://static.tigerbbs.com/9dacd5d2a7077a41b394190b7ed47d47","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569549791948201","authorIdStr":"3569549791948201"},"themes":[],"htmlText":"这篇文章不错，转发给大家看看","listText":"这篇文章不错，转发给大家看看","text":"这篇文章不错，转发给大家看看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/381405223952720","repostId":"377461792997392","repostType":1,"repost":{"id":377461792997392,"gmtCreate":1733182380221,"gmtModify":1746576330674,"author":{"id":"3459405299593947","authorId":"3459405299593947","name":"曹干","avatar":"https://static.tigerbbs.com/8710ff7a49df5b7bcdb6338bac4d0eb8","crmLevel":8,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3459405299593947","authorIdStr":"3459405299593947"},"themes":[],"htmlText":"我开仓了<a href=\"https://laohu8.com/S/TQQQ\">$纳指三倍做多ETF(TQQQ)$ </a>,呵呵，新高来了","listText":"我开仓了<a href=\"https://laohu8.com/S/TQQQ\">$纳指三倍做多ETF(TQQQ)$ </a>,呵呵，新高来了","text":"我开仓了$纳指三倍做多ETF(TQQQ)$ ,呵呵，新高来了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/377461792997392","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":814,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":226607236358392,"gmtCreate":1696332101119,"gmtModify":1696334095456,"author":{"id":"3569549791948201","authorId":"3569549791948201","name":"幸运无敌_8833","avatar":"https://static.tigerbbs.com/9dacd5d2a7077a41b394190b7ed47d47","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3569549791948201","authorIdStr":"3569549791948201"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$ </a>11。11。11。","listText":"<a href=\"https://laohu8.com/S/JD\">$京东(JD)$ </a>11。11。11。","text":"$京东(JD)$ 11。11。11。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/226607236358392","repostId":"1150270900","repostType":2,"repost":{"id":"1150270900","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1696330222,"share":"https://www.laohu8.com/m/news/1150270900?lang=&edition=full","pubTime":"2023-10-03 18:50","market":"us","language":"zh","title":"美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150270900","media":"老虎资讯综合","summary":"10月3日，Point Biopharma盘前直线涨超82%，礼来以12.50美元/股的价格将其收购","content":"<html><head></head><body><p>10月3日，Point Biopharma盘前直线涨超82%，<a href=\"https://laohu8.com/S/LLY\">礼来</a>将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2babea8249e8c38accee176b179d490\" title=\"\" tg-width=\"817\" tg-height=\"480\"/></p><p>资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2023-10-03 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>10月3日，Point Biopharma盘前直线涨超82%，<a href=\"https://laohu8.com/S/LLY\">礼来</a>将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2babea8249e8c38accee176b179d490\" title=\"\" tg-width=\"817\" tg-height=\"480\"/></p><p>资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","PNT":"POINT BIOPHARMA GLOBAL INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4581":"高盛持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LLY":"礼来"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150270900","content_text":"10月3日，Point Biopharma盘前直线涨超82%，礼来将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。","news_type":1,"symbols_score_info":{"LLY":1,"PNT":1.1}},"isVote":1,"tweetType":1,"viewCount":1006,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
